Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03617484
Title Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

mantle cell lymphoma

Therapies

Bortezomib + Ibrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.